New Zealand is prescribing up to seven times more puberty blockers to young transgender patients than other similar countries, new analysis shows.
Prescribing rates have fallen slightly in the last two years, possibly because of growing caution in some countries about possible long-term effects.
But researchers said the use of the puberty-stalling hormones remained relatively high at a time when overseas jurisdictions were becoming increasingly restrictive about their use.
The Government has recently announced its plan to modernise the regulation of medicines and medical devices by replacing the Medicines Act 1981 with a new Medical Products Bill (Bill). Read...
Proceedings of the Health New Zealand Te Whatu Ora, University of Auckland and AUT Collaborative Research Symposium 2024. Read...
Despite three decades of policy initiatives to improve integration of health care, delivery of health care in New Zealand remains fragmented, and health inequities persist for Māori and other high priority populations. Read...
HEALTH SERVICES AND SYSTEMS
EQUITY
Exploring the impacts of the health system on minorities within the population, notably including Māori, Pacifica, Asians and LGBTQI.
DRUGS, DEVICE AND DIAGNOSTICS
PUBLIC HEALTH
DIGITAL HEALTH
TE TIRITI